News and Conferences

Recognised by drug developers world-wide, Transpharmation’s client base continues to grow. With the expansion of therapeutic indications offered, the move to new, state of the art research facilities at Discovery Park in Kent is perfectly timed to hit the ground running from January 2021. With a vast array of laboratory and office space, managed by the hugely experienced company Agenda Life Sciences, Transpharmation’s scientists will have everything they need in place to deliver scientific excellence, remaining focussed on the important drug discovery work we carry out for our clients. 

Discovery Park, home to many specialist research companies, was recently named a Life Sciences Opportunity Zone by the UK Government’s Offices for Life Sciences. This multi-million pound site is known for its heritage of scientific excellence and delivery of new treatments for patients. With strong transport links to
airports, trains and ports it is ideally positioned for Transpharmation’s growing global customer portfolio.

Whilst Transpharmation will retain their facilities at The London Bioscience Innovation Centre, Royal Veterinary College and Trinity College Institute of Neuroscience, Dublin, the move to Discovery Park, on their 10th year anniversary, is a pivotal point in the company’s history and sets the agenda for their future growth.

Official press release

Transpharmation Ltd are pleased to sponsor Neuroscience Ireland’s Young Investigator Symposium, taking place on 6th November in Dublin https://www.bna.org.uk/mediacentre/events/neuroscience-ireland-young-investigator-symposium/ We’re also delighted that one of our young scientists, Erwina Stojek, has been selected to talk about her recent study on a new therapeutic target for aggressive behaviour. If you would like to see Erwina’s study or find out more about how we could help with your studies, please contact us

We are looking forward to entering this sell out virtual inflammasome therapeutics summit https://bit.ly/2J8g17f to hear from
leading experts around the world, dedicated to overcoming challenges in developing clinically effective
inflammasome therapeutics. Thank you to Inflammasome Therapeutics, GSK, and Novartis for putting it on.

As experts in preclinical neuroscience, we look forward to attending the 25th annual international congress of the World Muscle Society and making contact with other participants.  https://www.worldmusclesociety.org/web_pages/view/home Already involved in the EU-funded Brain Involvement in Dystrophinopathies, (BIND) project, our combined research aims at achieving ground-breaking progress in the understanding and treatment of neuropsychiatric comorbidities affecting Duchenne and Becker muscular dystrophy patients. For more information about our work in this particular field please email 

The study of Alzheimer’s Disease is one of a wide range of Transpharmation’s preclinical specialisms. We are looking forward to having a recorded presentation of a recent study showing at the 21st International Conference on Alzheimer's Drug Discovery; ‘Peripheral Blood Mononuclear Cells (PBMCs): Implications for screening novel anti-inflammatories in Alzheimer’s Disease (AD).’ Please see here for further detail: publications / preclinical services. Please feel free to contact us about how we might be able to help you with your Alzheimer’s Disease studies.